What hinders Indian pharma companies from making drugs for rare diseases

Challenges include complex regulations, prohibitive costs and conventional, non-innovative trial designs. Changes to clinical trial rules to accommodate flexible trial designs, bringing in AI and simplifying approval processes could go a long way toward promoting new drug R&D in India